Ardelyx

ARDXApproved

Ardelyx is a commercial-stage biopharmaceutical company pioneering novel, targeted therapies for cardiorenal and metabolic conditions. The company has achieved significant milestones with two FDA-approved products, XPHOZAH for hyperphosphatemia in dialysis patients and IBSRELA for IBS-C, both based on its NHE3 sodium transporter inhibition platform. Ardelyx continues to advance its pipeline while commercializing its approved therapies, positioning itself at the intersection of nephrology, cardiology, and gastroenterology. The company's strategy focuses on addressing significant unmet medical needs through its unique mechanism of action.

Market Cap

$1.3B

Employees

150-200

Focus

Biotech

ARDX · Stock Price

USD 5.31+4.25 (+400.94%)

Historical price data

AI Company Overview

Technology Platform

Proprietary NHE3 (sodium/hydrogen exchanger isoform 3) inhibitor platform that targets ion transport in the gastrointestinal tract to treat cardiorenal and metabolic diseases with minimal systemic exposure.

Pipeline Snapshot

27 drugs in pipeline, 11 in Phase 3

Drug	Indication	Stage
Tenapanor + Sevelamer Carbonate	Hyperphosphatemia	Approved
Tenapanor	Chronic Kidney Disease Requiring Chronic Dialysis	Approved
Tenapanor	IBS	Approved
Tenapanor + Placebo	Constipation Predominant Irritable Bowel Syndrome	Phase 3
Tenapanor	Irritable Bowel Syndrome With Constipation (IBS-C)	Phase 3

Funding History

Total raised: $165M

IPO$60MUndisclosedFeb 6, 2014

Series C$40MNew Enterprise AssociatesJun 15, 2013

Series B$35MNew Enterprise AssociatesJun 15, 2011

Series A$30MCanaan PartnersJun 15, 2008

FDA Approved Drugs

XPHOZAHNDAOct 17, 2023

IBSRELANDASep 12, 2019

Opportunities

Significant growth opportunity exists in expanding XPHOZAH adoption among the 550,000 U.S.

dialysis patients and increasing IBSRELA market share in the large IBS-C population.

The NHE3 platform offers potential expansion into additional indications like hyperkalemia and resistant hypertension, representing multi-billion dollar markets.

Geographic expansion through partnerships in international markets provides additional revenue potential.

Risk Factors

Commercial execution risks include challenges in penetrating the cost-sensitive dialysis market and competing against established IBS-C therapies.

Pipeline concentration risk exists with heavy reliance on the tenapanor molecule.

The company faces reimbursement hurdles for XPHOZAH and competitive pressure from larger pharmaceutical companies with greater resources.

Competitive Landscape

In hyperphosphatemia, Ardelyx competes against traditional phosphate binders (sevelamer, lanthanum) and newer agents like Auryxia, differentiated by XPHOZAH's novel non-binder mechanism and lower pill burden. In IBS-C, competitors include Linzess, Trulance, and Amitiza, with IBSRELA offering a distinct mechanism of action. Ardelyx's first-in-class science provides differentiation but requires effective commercialization against well-resourced competitors.

Publications

Patents

Pipeline

FDA Approvals